Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of majo…
Biotechnology
US, New York [HQ]
Ratios
11 Sheets · Starting from 2023Margins, Growth Rates In %
| Ratio | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| Gross Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | 89.61 | 87.84 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | -395.24 | -88.41 | |
| Operating Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | -352.74 | -67.59 | |
|
EPS Growth
|
- - | -176.47 | -87.23 | -61.36 | 10.56 | 9.45 | -78.26 | -38.05 | -26.86 | -35.38 | -8.44 | |
| EPS USD | -17.00 | -47.00 | -88.00 | -142.00 | -127.00 | -115.00 | -205.00 | -283.00 | -359.00 | -486.00 | -527.00 | |
| Return on Assets (ROA) | -103.30 | -215.35 | -21.52 | -71.19 | -81.40 | -201.35 | -31.60 | -56.62 | 39.88 | -59.66 | -40.67 | |
| Return on Equity (ROE) | 106.85 | 187.37 | 56.20 | 57.10 | 37.79 | 28.79 | 39.62 | 37.80 | 32.98 | -180.52 | -125.27 | |
| Return on Invested Capital (ROIC) | -102.31 | -264.54 | 55.25 | 74.24 | 42.58 | 35.81 | 43.96 | 44.40 | 35.90 | -91.33 | -49.59 | |
| Solvency | ||||||||||||
| Equity Ratio | - - | -100 | - - | -100 | -200 | -600 | - - | -100 | 100 | - - | - - | |
| Debt/Assets | 182.40 | 160.89 | - - | 25.49 | 27.94 | 44.94 | 9.04 | 26.93 | -14.69 | 28.56 | 30.49 | |
| Debt/Equity | -188.66 | -139.98 | - - | -20.44 | -12.97 | -6.43 | -11.33 | -17.98 | -12.15 | 86.42 | 93.91 | |
| Debt/EBITDA | -94.48 | -68.02 | 694.36 | 99.30 | 89.36 | 21.63 | 298.08 | 134.98 | 29.48 | 62.10 | 113.49 | |
|
Debt/Capitalization
|
212.79 | 350.14 | - - | -25.70 | -14.90 | -6.87 | -12.78 | -21.92 | -13.83 | 46.36 | 48.43 | |
| Long-Term Debt/Capitalization | - - | 358.51 | - - | -24.81 | -9.53 | -3.48 | -10.93 | -21.27 | -13.63 | 46.25 | 48.25 | |
| Interest Debt per Share USD | 0.33 | 0.53 | 0.08 | 0.52 | 0.50 | 0.30 | 0.62 | 1.42 | 1.47 | 2.51 | 4.09 | |
| Debt Growth | - - | 17.18 | -100.00 | - - | 1.98 | -30.42 | 188.46 | 151.44 | -0.83 | 90.47 | 96.84 | |
| Liquidity | ||||||||||||
| Current Ratio | 50.84 | 282.10 | 1,863.03 | 529.92 | 289.93 | 140.59 | 899.70 | 785.16 | 375.10 | 254.39 | 363.16 | |
| Quick Ratio | 50.61 | 269.15 | 1,825.16 | 510.67 | 279.43 | 129.08 | 898.01 | 784.53 | 374.91 | 247.04 | 346.42 | |
| Cash Ratio | 50.61 | 269.15 | 1,825.16 | 510.67 | 279.43 | 129.08 | 898.01 | 784.53 | 374.91 | 208.00 | 278.13 | |
| Operating Cash Flow Ratio | - - | -400 | -200 | -200 | -200 | -200 | -100 | -300 | -400 | -100 | -100 | |
| Turnover | ||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | 120.32 | 217.37 | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | 132.73 | 285.38 | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | 0.34 | 0.58 | 8.79 | 13.46 | 80.88 | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | 15.10 | 46.00 | |
| Fixed Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | 4,378.42 | 3,552.11 | |
| Coverage | ||||||||||||
| Interest Coverage | -562.19 | -253.97 | -1,005.11 | -20,799.48 | -2,026.89 | -2,913.73 | -5,425.02 | -3,863.90 | -2,189.35 | -2,406.42 | -2,834.45 | |
| Asset Coverage | - - | - - | - - | 300 | 200 | 100 | 900 | 300 | -700 | 100 | 200 | |
| Cash Flow Coverage (CFGR) | -42.63 | -102.53 | - - | -218.50 | -266.52 | -434.88 | -232.63 | -156.52 | -217.71 | -123.05 | -80.90 | |
| EBITDA Coverage | -500 | -100 | -700 | -20,400 | -2,000 | -2,800 | -5,400 | -3,800 | -2,100 | -2,300 | -2,700 | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -1.95 | -5.40 | -9.54 | -21.04 | -22.70 | -40.85 | -1.98 | -3.48 | -9.50 | -6.31 | -6.62 | |
|
Price/Earnings (P/E)
|
-5,130.32 | -1,852.41 | -1,048.65 | -475.22 | -440.45 | -244.83 | -5,045.91 | -2,876.26 | -1,053.21 | -1,585.60 | -1,511.21 | |
| Price/Earnings Growth (PEG) | - - | -10.50 | -12.02 | -7.74 | 41.70 | 25.91 | -64.48 | -75.59 | -39.22 | -44.82 | -179.13 | |
|
Price/Book (P/B)
|
-5,481.53 | -3,470.80 | -589.36 | -271.33 | -166.46 | -70.49 | -1,999.10 | -1,087.26 | -347.32 | 2,862.26 | 1,893.10 | |
| Price/Tangible Book (P/TB) | -5,481.53 | -3,470.80 | -589.36 | -271.33 | -166.46 | -70.49 | -1,999.10 | -1,087.26 | -347.32 | 2,862.26 | 1,893.10 | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | - - | - - | - - | - - | 6,266.93 | 1,336.07 | |
|
Price/Cash Flow (P/CF)
|
-6,814.87 | -2,418.31 | -1,488.55 | -607.42 | -481.58 | -252.25 | -7,582.38 | -3,863.60 | -1,313.21 | -2,691.42 | -2,492.00 | |
| Price/Free CF (P/FCF) | -6,814.87 | -2,418.31 | -1,484.52 | -604.45 | -481.40 | -251.98 | -7,579.75 | -3,861.34 | -1,309.49 | -2,675.30 | -2,482.04 | |
| Price/Operating CF (P/OCF) | -6,814.87 | -2,418.31 | -1,488.55 | -607.42 | -481.58 | -252.25 | -7,582.38 | -3,863.60 | -1,313.21 | -2,691.42 | -2,492.00 |